IMUGENE LIMITED - Announcements

Market Cap $357.0M Add to my watchlist

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IMU	PD1-Vaxx Clinical Trial Supply Agreement with Roche	PRICE SENSITIVE	28/01/22	107.17KB	Share
IMU	HER-Vaxx Immunotherapy Patent Granted in Europe	PRICE SENSITIVE	28/01/22	123.17KB	Share
IMU	Imugene Receives $6.54 million R&D Tax Incentive	PRICE SENSITIVE	06/01/22	83.04KB	Share
IMU	South Korea HERVaxx Patent Grant	PRICE SENSITIVE	06/01/22	94.04KB	Share
IMU	Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx	PRICE SENSITIVE	04/01/22	96.13KB	Share
IMU	FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX	PRICE SENSITIVE	13/12/21	177.59KB	Share
IMU	FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA	PRICE SENSITIVE	13/12/21	127.52KB	Share
IMU	Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc	PRICE SENSITIVE	07/12/21	158.38KB	Share
IMU	S&P DJI Announces December 2021 Quarterly Rebalance	PRICE SENSITIVE	03/12/21	92.25KB	Share
IMU	Clinical Trial Supply Agreement with Merck KGaA and Pfizer	PRICE SENSITIVE	16/11/21	124.99KB	Share
IMU	Investor Presentation Imugene Eureka Therapeutics	PRICE SENSITIVE	01/11/21	2.22MB	Share
IMU	Imugene and Eureka Therapeutics onCARlytics Collaboration	PRICE SENSITIVE	01/11/21	145.54KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/10/21	3.24MB	Share
IMU	FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC	PRICE SENSITIVE	20/10/21	104.78KB	Share
IMU	Imugene HER-Vaxx Immunotherapy Patent Granted in Japan	PRICE SENSITIVE	22/09/21	145.67KB	Share
IMU	S&P DJI Announces September 2021 Quarterly Rebalance	PRICE SENSITIVE	03/09/21	108.28KB	Share
IMU	Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials	PRICE SENSITIVE	01/09/21	151.61KB	Share
IMU	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	30/08/21	1.95MB	Share
IMU	Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx	PRICE SENSITIVE	27/08/21	141.61KB	Share
IMU	Response to ASX Query	PRICE SENSITIVE	23/08/21	242.77KB	Share
IMU	Research partnership with Celularity for solid tumors	PRICE SENSITIVE	05/08/21	205.02KB	Share
IMU	Prospectus for SPP and Placement Options Offer	PRICE SENSITIVE	29/07/21	462.85KB	Share
IMU	Imugene completes $90 M placement and launches $5 M SPP	PRICE SENSITIVE	29/07/21	171.33KB	Share
IMU	Trading Halt	PRICE SENSITIVE	27/07/21	179.35KB	Share
IMU	Appendix 4C - Quarterly Report	PRICE SENSITIVE	23/07/21	404.23KB	Share
IMU	FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC	PRICE SENSITIVE	02/07/21	133.12KB	Share
IMU	Investor Presentation	PRICE SENSITIVE	18/05/21	3.1MB	Share
IMU	IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS	PRICE SENSITIVE	18/05/21	150.1KB	Share
IMU	Prestigious Research Journal Publish HER-Vaxx Phase 1B Data	PRICE SENSITIVE	29/04/21	124.23KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/21	329.82KB	Share
IMU	Imugene announces clinical milestone for HER-Vaxx	PRICE SENSITIVE	21/04/21	125.23KB	Share
IMU	Imugene Oncolytic Virus Presentation at AACR 2021 Meeting	PRICE SENSITIVE	12/04/21	102.64KB	Share
IMU	Imugene HER-Vaxx Presentation at AACR 2021 Meeting	PRICE SENSITIVE	12/04/21	128KB	Share
IMU	Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX	PRICE SENSITIVE	07/04/21	131.8KB	Share
IMU	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
IMU	Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting	PRICE SENSITIVE	11/03/21	122.7KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/21	6.16MB	Share
IMU	Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial	PRICE SENSITIVE	12/02/21	124.85KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	272.19KB	Share
IMU	Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial	PRICE SENSITIVE	21/01/21	126.73KB	Share
IMU	IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM	PRICE SENSITIVE	07/01/21	107.46KB	Share
IMU	Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial	PRICE SENSITIVE	17/12/20	136.02KB	Share
IMU	Imugene Receives $4.82 million R&D Tax Incentive	PRICE SENSITIVE	10/12/20	129.13KB	Share
IMU	Imugene First Patient Dosed in PD1-VAXX Clinical Trial	PRICE SENSITIVE	01/12/20	120.02KB	Share
IMU	Imugene HER Vaxx shows positive Overall Survival in trial	PRICE SENSITIVE	23/11/20	134.83KB	Share
IMU	Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA	PRICE SENSITIVE	02/11/20	111.65KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/20	366.05KB	Share
IMU	Imugene Immunotherapy Combination Patent Granted in US	PRICE SENSITIVE	02/10/20	133.51KB	Share
IMU	Imugene Secures $5.7 million Option Underwriting Agreement	PRICE SENSITIVE	09/09/20	144.01KB	Share
IMU	Imugene Receives PD1-VAXX Ethics Trial Approval in USA	PRICE SENSITIVE	03/09/20	143.66KB	Share
IMU	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	31/08/20	4.81MB	Share
IMU	Imugene Receives Third PD1-VAXX Ethics Trial Approval	PRICE SENSITIVE	21/08/20	126.29KB	Share
IMU	Imugene Receives Clinical Guidance from US FDA for Vaxinia	PRICE SENSITIVE	06/08/20	142.12KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/20	408.9KB	Share
IMU	Imugene Receives Second PD1-VAXX Ethics Trial Approval	PRICE SENSITIVE	17/07/20	145.69KB	Share
IMU	Imugene Receives Ethics Approval to Start PD1-VAXX Trial	PRICE SENSITIVE	14/07/20	145.97KB	Share
IMU	Imugene HER-Vaxx Phase 2 Clinical Update	PRICE SENSITIVE	04/05/20	114.71KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/20	684.52KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/20	5.84MB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	348.47KB	Share
IMU	Imugene PD1-Vaxx Immunotherapy Update	PRICE SENSITIVE	28/01/20	138.09KB	Share
IMU	Imugene HER-Vaxx Immunotherapy Patent Granted in US	PRICE SENSITIVE	14/01/20	123.55KB	Share
IMU	Prospectus	PRICE SENSITIVE	02/12/19	556.91KB	Share
IMU	Imugene Share Placement to raise $24.6 million	PRICE SENSITIVE	02/12/19	134.16KB	Share
IMU	Trading Halt	PRICE SENSITIVE	28/11/19	360.08KB	Share
IMU	Imugene Receives $4.13 million R&D Tax Incentive	PRICE SENSITIVE	04/11/19	103.43KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/19	389.27KB	Share
IMU	US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy	PRICE SENSITIVE	23/10/19	246.29KB	Share
IMU	CF33 Oncolytic Virus Clinical Trial Program Update	PRICE SENSITIVE	21/10/19	86.78KB	Share
IMU	Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO	PRICE SENSITIVE	01/10/19	156.74KB	Share
IMU	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	30/08/19	5.25MB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/19	247.66KB	Share
IMU	Investor Presentation - Proposed Acquisition	PRICE SENSITIVE	15/07/19	7.06MB	Share
IMU	Imugene Enhances Portfolio with Compelling Oncolytic Virus	PRICE SENSITIVE	15/07/19	91.67KB	Share
IMU	New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI	PRICE SENSITIVE	08/07/19	79.11KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	16/04/19	270.77KB	Share
IMU	IMU presents new mimotope PD-1 vaccine data at AACR	PRICE SENSITIVE	03/04/19	160.49KB	Share
IMU	IMU presents new KEY-Vaxx and B-Vaxx data at AACR	PRICE SENSITIVE	02/04/19	164.88KB	Share
IMU	IMU presents positive new HER-Vaxx data at AACR	PRICE SENSITIVE	02/04/19	167.49KB	Share
IMU	IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx	PRICE SENSITIVE	20/03/19	75.86KB	Share
IMU	Imugene doses first patient in HER-Vaxx phase 2 trial	PRICE SENSITIVE	14/03/19	96.99KB	Share
IMU	IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR	PRICE SENSITIVE	04/03/19	100.39KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	4.58MB	Share
IMU	Pause in Trading	PRICE SENSITIVE	28/02/19	116KB	Share
IMU	Imugene Announces Presentation on HER-Vaxx at the AACR 2019	PRICE SENSITIVE	28/02/19	85.19KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	30/01/19	557.58KB	Share
IMU	Investor Presentation	PRICE SENSITIVE	10/01/19	11.83MB	Share
IMU	IMU Meets Endpoints in Phase 1b Gastric Cancer Trial	PRICE SENSITIVE	17/12/18	114.47KB	Share
IMU	Imugene Advances to Phase 2 in Gastric Cancer Trial	PRICE SENSITIVE	13/11/18	366.09KB	Share
IMU	Imugene Receives $1.85 million R&D Tax Incentive	PRICE SENSITIVE	09/11/18	101.15KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	1.05MB	Share
IMU	Imugene commences cGMP manufacture of PD-1 cancer vaccine	PRICE SENSITIVE	21/09/18	141.95KB	Share
IMU	Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment	PRICE SENSITIVE	11/09/18	393.79KB	Share
IMU	Appendix 4E and Audited Financial Report	PRICE SENSITIVE	31/08/18	539.83KB	Share
IMU	Appendix 4C - Quarterly and Business Update	PRICE SENSITIVE	31/07/18	555.82KB	Share
IMU	PD-1 cancer vaccine development update	PRICE SENSITIVE	23/07/18	399.17KB	Share
IMU	Response to ASX Query	PRICE SENSITIVE	08/06/18	496.2KB	Share
IMU	Prospectus	PRICE SENSITIVE	07/06/18	976.05KB	Share
IMU	IMUGENE RAISES $20.1 MILLION	PRICE SENSITIVE	07/06/18	584.16KB	Share
IMU	Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio	PRICE SENSITIVE	07/06/18	341.69KB	Share

IMU PD1-Vaxx Clinical Trial Supply Agreement with Roche
28/01/22	PRICE SENSITIVE	107.17KB	Share
IMU HER-Vaxx Immunotherapy Patent Granted in Europe
28/01/22	PRICE SENSITIVE	123.17KB	Share
IMU Imugene Receives $6.54 million R&D Tax Incentive
06/01/22	PRICE SENSITIVE	83.04KB	Share
IMU South Korea HERVaxx Patent Grant
06/01/22	PRICE SENSITIVE	94.04KB	Share
IMU Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
04/01/22	PRICE SENSITIVE	96.13KB	Share
IMU FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX
13/12/21	PRICE SENSITIVE	177.59KB	Share
IMU FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA
13/12/21	PRICE SENSITIVE	127.52KB	Share
IMU Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
07/12/21	PRICE SENSITIVE	158.38KB	Share
IMU S&P DJI Announces December 2021 Quarterly Rebalance
03/12/21	PRICE SENSITIVE	92.25KB	Share
IMU Clinical Trial Supply Agreement with Merck KGaA and Pfizer
16/11/21	PRICE SENSITIVE	124.99KB	Share
IMU Investor Presentation Imugene Eureka Therapeutics
01/11/21	PRICE SENSITIVE	2.22MB	Share
IMU Imugene and Eureka Therapeutics onCARlytics Collaboration
01/11/21	PRICE SENSITIVE	145.54KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
22/10/21	PRICE SENSITIVE	3.24MB	Share
IMU FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC
20/10/21	PRICE SENSITIVE	104.78KB	Share
IMU Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
22/09/21	PRICE SENSITIVE	145.67KB	Share
IMU S&P DJI Announces September 2021 Quarterly Rebalance
03/09/21	PRICE SENSITIVE	108.28KB	Share
IMU Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
01/09/21	PRICE SENSITIVE	151.61KB	Share
IMU Appendix 4E and Full Year Statutory Accounts
30/08/21	PRICE SENSITIVE	1.95MB	Share
IMU Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
27/08/21	PRICE SENSITIVE	141.61KB	Share
IMU Response to ASX Query
23/08/21	PRICE SENSITIVE	242.77KB	Share
IMU Research partnership with Celularity for solid tumors
05/08/21	PRICE SENSITIVE	205.02KB	Share
IMU Prospectus for SPP and Placement Options Offer
29/07/21	PRICE SENSITIVE	462.85KB	Share
IMU Imugene completes $90 M placement and launches $5 M SPP
29/07/21	PRICE SENSITIVE	171.33KB	Share
IMU Trading Halt
27/07/21	PRICE SENSITIVE	179.35KB	Share
IMU Appendix 4C - Quarterly Report
23/07/21	PRICE SENSITIVE	404.23KB	Share
IMU FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC
02/07/21	PRICE SENSITIVE	133.12KB	Share
IMU Investor Presentation
18/05/21	PRICE SENSITIVE	3.1MB	Share
IMU IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS
18/05/21	PRICE SENSITIVE	150.1KB	Share
IMU Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
29/04/21	PRICE SENSITIVE	124.23KB	Share
IMU Appendix 4C - quarterly
23/04/21	PRICE SENSITIVE	329.82KB	Share
IMU Imugene announces clinical milestone for HER-Vaxx
21/04/21	PRICE SENSITIVE	125.23KB	Share
IMU Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
12/04/21	PRICE SENSITIVE	102.64KB	Share
IMU Imugene HER-Vaxx Presentation at AACR 2021 Meeting
12/04/21	PRICE SENSITIVE	128KB	Share
IMU Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
07/04/21	PRICE SENSITIVE	131.8KB	Share
IMU S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
IMU Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
11/03/21	PRICE SENSITIVE	122.7KB	Share
IMU Half Yearly Report and Accounts
26/02/21	PRICE SENSITIVE	6.16MB	Share
IMU Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
12/02/21	PRICE SENSITIVE	124.85KB	Share
IMU Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	272.19KB	Share
IMU Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
21/01/21	PRICE SENSITIVE	126.73KB	Share
IMU IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM
07/01/21	PRICE SENSITIVE	107.46KB	Share
IMU Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
17/12/20	PRICE SENSITIVE	136.02KB	Share
IMU Imugene Receives $4.82 million R&D Tax Incentive
10/12/20	PRICE SENSITIVE	129.13KB	Share
IMU Imugene First Patient Dosed in PD1-VAXX Clinical Trial
01/12/20	PRICE SENSITIVE	120.02KB	Share
IMU Imugene HER Vaxx shows positive Overall Survival in trial
23/11/20	PRICE SENSITIVE	134.83KB	Share
IMU Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
02/11/20	PRICE SENSITIVE	111.65KB	Share
IMU Appendix 4C - quarterly
27/10/20	PRICE SENSITIVE	366.05KB	Share
IMU Imugene Immunotherapy Combination Patent Granted in US
02/10/20	PRICE SENSITIVE	133.51KB	Share
IMU Imugene Secures $5.7 million Option Underwriting Agreement
09/09/20	PRICE SENSITIVE	144.01KB	Share
IMU Imugene Receives PD1-VAXX Ethics Trial Approval in USA
03/09/20	PRICE SENSITIVE	143.66KB	Share
IMU Appendix 4E & Annual Report to shareholders
31/08/20	PRICE SENSITIVE	4.81MB	Share
IMU Imugene Receives Third PD1-VAXX Ethics Trial Approval
21/08/20	PRICE SENSITIVE	126.29KB	Share
IMU Imugene Receives Clinical Guidance from US FDA for Vaxinia
06/08/20	PRICE SENSITIVE	142.12KB	Share
IMU Appendix 4C - quarterly
27/07/20	PRICE SENSITIVE	408.9KB	Share
IMU Imugene Receives Second PD1-VAXX Ethics Trial Approval
17/07/20	PRICE SENSITIVE	145.69KB	Share
IMU Imugene Receives Ethics Approval to Start PD1-VAXX Trial
14/07/20	PRICE SENSITIVE	145.97KB	Share
IMU Imugene HER-Vaxx Phase 2 Clinical Update
04/05/20	PRICE SENSITIVE	114.71KB	Share
IMU Appendix 4C - quarterly
24/04/20	PRICE SENSITIVE	684.52KB	Share
IMU Half Yearly Report and Accounts
26/02/20	PRICE SENSITIVE	5.84MB	Share
IMU Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	348.47KB	Share
IMU Imugene PD1-Vaxx Immunotherapy Update
28/01/20	PRICE SENSITIVE	138.09KB	Share
IMU Imugene HER-Vaxx Immunotherapy Patent Granted in US
14/01/20	PRICE SENSITIVE	123.55KB	Share
IMU Prospectus
02/12/19	PRICE SENSITIVE	556.91KB	Share
IMU Imugene Share Placement to raise $24.6 million
02/12/19	PRICE SENSITIVE	134.16KB	Share
IMU Trading Halt
28/11/19	PRICE SENSITIVE	360.08KB	Share
IMU Imugene Receives $4.13 million R&D Tax Incentive
04/11/19	PRICE SENSITIVE	103.43KB	Share
IMU Appendix 4C - quarterly
25/10/19	PRICE SENSITIVE	389.27KB	Share
IMU US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
23/10/19	PRICE SENSITIVE	246.29KB	Share
IMU CF33 Oncolytic Virus Clinical Trial Program Update
21/10/19	PRICE SENSITIVE	86.78KB	Share
IMU Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
01/10/19	PRICE SENSITIVE	156.74KB	Share
IMU Appendix 4E & Annual Report to shareholders
30/08/19	PRICE SENSITIVE	5.25MB	Share
IMU Appendix 4C - quarterly
26/07/19	PRICE SENSITIVE	247.66KB	Share
IMU Investor Presentation - Proposed Acquisition
15/07/19	PRICE SENSITIVE	7.06MB	Share
IMU Imugene Enhances Portfolio with Compelling Oncolytic Virus
15/07/19	PRICE SENSITIVE	91.67KB	Share
IMU New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
08/07/19	PRICE SENSITIVE	79.11KB	Share
IMU Appendix 4C - Quarterly and Business Update
16/04/19	PRICE SENSITIVE	270.77KB	Share
IMU IMU presents new mimotope PD-1 vaccine data at AACR
03/04/19	PRICE SENSITIVE	160.49KB	Share
IMU IMU presents new KEY-Vaxx and B-Vaxx data at AACR
02/04/19	PRICE SENSITIVE	164.88KB	Share
IMU IMU presents positive new HER-Vaxx data at AACR
02/04/19	PRICE SENSITIVE	167.49KB	Share
IMU IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
20/03/19	PRICE SENSITIVE	75.86KB	Share
IMU Imugene doses first patient in HER-Vaxx phase 2 trial
14/03/19	PRICE SENSITIVE	96.99KB	Share
IMU IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
04/03/19	PRICE SENSITIVE	100.39KB	Share
IMU Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	4.58MB	Share
IMU Pause in Trading
28/02/19	PRICE SENSITIVE	116KB	Share
IMU Imugene Announces Presentation on HER-Vaxx at the AACR 2019
28/02/19	PRICE SENSITIVE	85.19KB	Share
IMU Appendix 4C - Quarterly and Business Update
30/01/19	PRICE SENSITIVE	557.58KB	Share
IMU Investor Presentation
10/01/19	PRICE SENSITIVE	11.83MB	Share
IMU IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
17/12/18	PRICE SENSITIVE	114.47KB	Share
IMU Imugene Advances to Phase 2 in Gastric Cancer Trial
13/11/18	PRICE SENSITIVE	366.09KB	Share
IMU Imugene Receives $1.85 million R&D Tax Incentive
09/11/18	PRICE SENSITIVE	101.15KB	Share
IMU Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	1.05MB	Share
IMU Imugene commences cGMP manufacture of PD-1 cancer vaccine
21/09/18	PRICE SENSITIVE	141.95KB	Share
IMU Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
11/09/18	PRICE SENSITIVE	393.79KB	Share
IMU Appendix 4E and Audited Financial Report
31/08/18	PRICE SENSITIVE	539.83KB	Share
IMU Appendix 4C - Quarterly and Business Update
31/07/18	PRICE SENSITIVE	555.82KB	Share
IMU PD-1 cancer vaccine development update
23/07/18	PRICE SENSITIVE	399.17KB	Share
IMU Response to ASX Query
08/06/18	PRICE SENSITIVE	496.2KB	Share
IMU Prospectus
07/06/18	PRICE SENSITIVE	976.05KB	Share
IMU IMUGENE RAISES $20.1 MILLION
07/06/18	PRICE SENSITIVE	584.16KB	Share
IMU Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
07/06/18	PRICE SENSITIVE	341.69KB	Share

REFRESH

First 2 3

(20min delay)
Last 4.8¢		Change -0.001(2.04%)		Mkt cap ! $357.0M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$279.2K	5.733M

Buyers (Bids)

No.	Vol.	Price($)
94	12992150	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	1795056	6

View Market Depth

No.	Vol.	Price($)
93	12942150	0.048
44	4009024	0.047
33	3946479	0.046
48	4998765	0.045
9	899955	0.044

Price($)	Vol.	No.
0.049	1795056	6
0.050	1199729	8
0.051	1430603	8
0.052	1994270	12
0.053	2727411	21

Last trade - 16.10pm 28/10/2024 (20 minute delay)


Last 4.9¢		Change -0.001 ( 1.02 %)
Open	High	Low	Volume
4.9¢	4.9¢	4.8¢	4644961
Last updated 15.59pm 28/10/2024 ?

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories